Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soli-CGM: Soliqua 100/33 in Uncontrolled T2DM
NCT05114590Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Jan 2022; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05114590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114590.